china-header

China

Aspen China has delivered double-digit revenue growth year-on-year since it was established in FY2017. Our portfolio is led by our Thrombosis and Anaesthetics Brands and also comprises some smaller global brands. Our product portfolio is well placed to deliver value to Chinese patients given our focus on high quality, stable supply and affordable medicines with strong brand equity.

Contribution to Group revenue

pic-11europe

Revenue contribution - by therapeutic category

pic-12europe
  • The China pharmaceutical sector was valued at USD92 billion as at 31 December 2018 and grew 6%versus the prior comparable period

Source: December 2018 IQVIA

STATISTICS

Number of products launched:

Nil

(2018: Nil)

Number of product recalls:

Nil

(2018: Nil)

In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:

0 – 2 years

Nil

3 – 5 years

USD16 million

Average staff turnover:

30,3%

(2018: 25,9%)

Number of work-related fatalities:

Nil

(2018: Nil)

Number of permanent employees:

june-06


Revenue
2019
R'million
2018 (CER)
R'million
change
%
Total 2 8722 54413
Regional Brands272129
Sterile Focus Brands2 8452 52313
Anaesthetics Brands1 9761 8745
Thrombosis Brands86964934

Note: Commercial Pharmaceuticals revenue is disclosed by customer geography.